SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-18-000223
Filing Date
2018-02-13
Accepted
2018-02-13 17:20:15
Documents
2
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 form5-02132018_020200.html 5  
1 form5-02132018_020200.xml 5 3464
2 ex24-02132018_020201.htm EX-24 5973
  Complete submission text file 0001415889-18-000223.txt   10916
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Issuer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1

Mailing Address C/OAZURRX BIOPHARMA,INC.760 PARKSIDE AVE DOWNSTATE BIOTECHNOLOGY INCUBATOR,STE217 BROOKLY NY 11226
Business Address
Riddell Alastair (Reporting) CIK: 0001681349 (see all company filings)

Type: 5 | Act: 34 | File No.: 001-37853 | Film No.: 18604933